Cycle Pharmaceuticals Ltd. has signed an agreement with Catalent to develop innovative formulations targeting rare metabolic and neurological disorders. The agreement covers four products and each will use Catalent’s Zydis® oral disintegrating tablet (ODT) and Zydis Ultra® technologies.  Zydis technology is recognized as one of the best performing ODTs and offers advantages over conventional oral dosage forms, including improved patient compliance, adherence and convenience. The Zydis Ultra pla...